Analysts Set Zoetis Inc. (NYSE:ZTS) PT at $191.00

Shares of Zoetis Inc. (NYSE:ZTS) have earned a consensus recommendation of “Moderate Buy” from the eleven analysts that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $180.00.

Several research firms have recently commented on ZTS. Argus restated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Piper Sandler lifted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Morgan Stanley decreased their price objective on Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a report on Monday. Finally, JPMorgan Chase & Co. dropped their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th.

Zoetis Price Performance

Shares of ZTS stock opened at $121.30 on Monday. Zoetis has a twelve month low of $117.26 and a twelve month high of $181.85. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a fifty day simple moving average of $142.21 and a two-hundred day simple moving average of $151.94. The stock has a market capitalization of $53.45 billion, a price-to-earnings ratio of 20.88, a P/E/G ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same quarter last year, the firm posted $1.58 earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts predict that Zoetis will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.6%. Zoetis’s payout ratio is presently 33.67%.

Institutional Trading of Zoetis

A number of institutional investors have recently bought and sold shares of the stock. Nova Wealth Management Inc. acquired a new position in Zoetis in the first quarter valued at approximately $25,000. 1248 Management LLC purchased a new position in shares of Zoetis during the 1st quarter valued at approximately $27,000. Halbert Hargrove Global Advisors LLC lifted its stake in shares of Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the period. Saudi Central Bank acquired a new position in shares of Zoetis in the 1st quarter valued at $29,000. Finally, REAP Financial Group LLC boosted its holdings in Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after buying an additional 131 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.